Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Marketing Status Prescription; Discontinued
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 70436-012; 70436-013; 50090-4806; 0054-0401; 46708-152; 70518-3195; 68382-469; 0591-3659; 71335-1815; 0054-0603; 70436-036; 71335-1753; 51407-023; 0591-4060; 50090-4388; 63304-191; 0591-3660; 14501-0068; 46708-153; 60687-607; 70771-1311; 68382-741; 71335-1975; 0054-0400; 51407-022; 63304-192; 63629-7524; 71335-1700; 70771-1312; 69766-025
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoaesthesia17.02.06.023--Not Available
Hypomania19.16.02.001--Not Available
Hyponatraemia14.05.04.0020.005922%
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Inappropriate affect19.04.01.0050.001269%Not Available
Increased appetite08.01.09.027; 14.03.01.0030.001269%Not Available
Influenza22.07.02.001; 11.05.03.0010.002538%Not Available
Influenza like illness08.01.03.0100.001269%
Insomnia19.02.01.002; 17.15.03.0020.014381%
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Intraocular pressure increased13.07.04.0020.001269%Not Available
Irritability19.04.02.013; 08.01.03.0110.008883%
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.000846%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000846%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Libido decreased21.03.02.005; 19.08.03.0010.001269%
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Logorrhoea19.19.02.001; 17.02.08.0060.000846%Not Available
Loss of consciousness17.02.04.0040.002961%Not Available
Low density lipoprotein13.12.01.011--Not Available
Malabsorption07.17.01.001; 14.02.01.0040.001692%
Malaise08.01.01.0030.018188%
Mania19.16.02.0020.003807%
Memory impairment19.20.01.003; 17.03.02.003--
Menopausal symptoms21.02.02.002--Not Available
Menorrhagia21.01.03.0020.001269%
Mental impairment19.21.02.003; 17.03.03.0020.001269%Not Available
Migraine24.03.05.003; 17.14.02.0010.001692%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 11 Pages